Sheridan said no significant differences in any of the efficacy end points were seen, which “was expected given the active control, small sample size, and exploratory phase 2 nature of this study.” Oct 28 news release about outpatient studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343466 In the other trial, hospital patients who were seriously ill with flu were treated for 5 days with either IV peramivir or oseltamivir, with similar results in both groups, including no deaths and a median of 4.0 days to hospital discharge, the company said. Oct 27 news release about hospital studyhttp://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=343132 Clinical stability was a composite measure based on temperature, oxygen saturation, respiratory rate, systolic blood pressure, and heart rate. For ethical reasons, the study included no placebo arm. In addition, both peramivir groups had significant improvements in a composite symptoms score, starting as early as 24 hours after treatment, the statement said. The drug was well-tolerated, with adverse-event profiles similar for the treatment and placebo groups. Hospital studyThe inpatient study was designed primarily to assess how long it would take patients with serious or life-threatening flu to become clinically stable with 5 days of treatment with peramivir or oseltamivir. The study was conducted at centers in the United States, Canada, Hong Kong, Singapore, Australia, New Zealand, and South Africa. “This phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza,” Dr. William P. Sheridan, chief medical officer of BioCryst, said in the news release. Secondary outcomes for all groups included no mortality, no clinical relapse, a median of 4.0 days to hospital discharge, and a median of 10.8 days to resumption of normal activities, the company reported. Sep 20, 2007, CIDRAP News story “Trial of injectable flu drug yields disappointing results” Sheridan also said that the zero mortality in the study is “an important finding worthy of follow-up,” given that a previous epidemiologic study showed a mortality rate of 10% in 219 patients who were not treated with neuraminidase inhibitors. See also: Page with link to recording of Oct 27 BioCryst teleconference (free registration required)http://investor.shareholder.com/biocryst/eventdetail.cfm?eventid=60565 Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder. In response to questions, he said the study was not designed to show differences between peramivir and oseltamivir. He said peramivir is important because it permits parenteral treatment of flu patients, adding, “At the ICAAC meeting the need for a parenteral drug for influenza has come up several times already. Also there’s concern about resistance to existing drugs, including oseltamivir.” The primary end point was time to alleviation of symptoms, which was 81.8 hours for the placebo group. The respective times for the 300-mg and 600-mg peramivir groups were 59.1 and 59.9 hours, both of which were significant reductions, the company said. Oct 31, 2008 (CIDRAP News) BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza. In one study, a single intravenous (IV) dose of peramivir in outpatients ill with flu reduced the duration of their symptoms by about 22 hours compared with a placebo group, a statistically significant difference, according to BioCryst, based in Birmingham, Ala. Neither set of results has yet been published in a peer-reviewed journal. The company described the inpatient study in a press release and a teleconference on Oct 27; the outpatient study was reported in an Oct 28 press release and a poster presentation at the 46th Interscience Conference on Antimicrobials and Chemotherapy/Infectious Diseases Society of America (ICAAC/IDSA) meeting this week in Washington, DC. Outpatient findingsThe outpatient study was sponsored and conducted in Japan by Shionogi & Co. Ltd., which in 2007 bought from BioCryst the rights to develop and market peramivir in Japan. “The time to clinical stability was 25.3 hours for all groups combined, with no statistically significant differences across treatment groups,” Sheridan reported during the Oct 27 conference call (a recording of which is available online). In the news release, Dr. Michael Ison of Northwestern University, principal investigator in the study, said, “This landmark study provides us great insight into the course of treatment for patients who are hospitalized for influenza. The results indicate a potential role for antiviral therapy, which is critical as currently there are no antivirals approved for patients hospitalized for acute serious or potentially life-threatening influenza.” The new findings come 13 months after the company reported disappointing results in an earlier phase 2 trial of the drug. In that study, flu patients who received injections of peramivir did better than a placebo group, but the difference was not significant. The company said at the time that the use of shorter needles than were used in an earlier trial probably resulted in inadequate doses. The study involved 296 patients who tested positive for influenza within 48 hours after symptom onset, BioCryst reported. The volunteers were divided into three groups, with 99 receiving 300 milligrams (mg) of peramivir IV, 97 receiving 600 mg of the drug IV, and 100 receiving an IV placebo. The investigators enrolled 122 patients who had flu confirmed by polymerase chain reaction. Of these, 41 received 75 mg of oseltamivir twice daily, 41 received 200 mg of IV peramivir twice daily, and 40 received 400 mg of IV peramivir twice daily.
The USC Marshall School of Business’ Sports Business Institute and the USA TODAY Sports Media Group announced a new partnership to create an online platform for covering the business of sports on Tuesday.The new website, “The Fields of Green,” will utilize curated blog posts, columns and multimedia to offer analysis on breaking news and trends in the sports industry. Combining the acumen of experts and key players in the industry, the site will provide insight on factors such as media trends and new technologies affecting the sports business.“We are so pleased to be working with the USA TODAY Sports Media Group. Fields of Green brings something completely new to the table: timely, incisive analysis of issues in sports from a business perspective,” said David Carter, executive director of the Sports Business Institute and a national authority on sports business and strategic marketing, in a press release. “It’s a niche that no one else is filling, and a tremendous opportunity to shed light on the developments driving the sports business industry today.”Founded in 2005, the Sports Business Institute, housed within USC Marshall, was the first of its kind at a major academic institution and, according to its website, is “focused on understanding and furthering the sports business industry” through collaborative events, research and student-led consulting. In 2010, the institute published the book Money Games: Profiting from the Convergence of Sports and Entertainment.The goal of the partnership is to combine the global expertise of Marshall’s SBI with the global reach of USA TODAY. SBI will provide in-depth analysis and feature content for the website, and USA TODAY will provide the administrative and technological infrastructure to create the new online platform. Formed in 2011, the Sport’s Media Group sites are consistently among the top five most visited sports sites in North America, according to analytics firm ComScore.“Fields of Green will leverage our position as the top source of sports news and information in the country to expose a broad audience to the USC Sports Business Institute’s cutting-edge insight and seasoned analysis,” Dave Morgan, president of the USA TODAY Sports Media Group, said in a press release. “The synergies between us make our two organizations a solid match.”
The second swimming meeting under the title ”H2O 2012” will be held on the 22nd December at the Olympic swimming pool Otoka. The organizer of this second swimming meeting in Sarajevo is the Swimming club ”H2O” from Sarajevo.The New Year’s swimming meeting will host more than twenty swimming clubs. The organizers of this event expect more that 500 contestants. The opening ceremony for this event is planned for Saturday, the 22nd December, at 09:45 a.m., while the official competition starts at 10:30 a.m.All swimming pools will be available for other visitors during the Swimming meeting ”H2O 2012”, so that both the competition and usual visitors can enjoy the services of the Olympic swimming pool Otoka.
After the rematch of the second qualifying round of the European League against FC Ferencváros, FC Željezničar will be left without one of its best players, Josip Kvesić.The left-back, who was irreplaceable in the young national team in the past and several times invited to the A team, is to continue with his career in the Turkish Premier League club FC Antalyaspor.According to the Turkish media, Josip already negotiated all the conditions of the transfer, and FC Željezničar will receive 100.000 Euros on the account of compensation.So far in his career, besides FC Željezničar Kvesić played for FC Široki Brijeg, FC Žilina and FC Varaždin.(Source: klix.ba)
6:00 PM Bayer Steer Classic – Cattle Ring Proceeding west from Dawson Co-op Mall parking lot on 102 Avenue to 12th StreetSouth on 12th street to 103rd AvenueEast on 103rd Avenue to 10th StreetSouth on 10th Street to 13th StreetSouth on 13th Street to 114th Avenue, terminating through the back entrance of the Northern Lights College Campus 7:30 PM Steer Classic Auction Sale – Auction Mart 1:00 PM Light Horse Show BC Angus Gold show Exhibits Open to Public 7:00 PM Wool Fleece Judging 10:30 PM Fireworks – Advertisement – Friday, August 12, 2011 4:00 PM Outdoor Stage – Jack Jackson Steak BBQ Opens – “Waterin’ Hole” 8:00 AM Food & Trade Fair Booths Open on Grounds 1:15 PM Wrangler Canadian Pro Rodeo Tour Grand Entry 1:30 PM Wrangler Canadian Professional Rodeo Tour Junior Cattle Classic Show Junior Sheep Show 8:30 AM Light Horse Show Parade Route: 2:00 PM Rising Star Talent Show Run Offs – Sound Stage 5:30 PM Crazy Cowgirls Trick Riding Kids Wild Horse Race Western Chuckwagon Assoc. Races 6:30 PM World Professional Chuckwagon Assoc. Races 8:30 PM Deere John Band performs in the Waterin’ Hole 3:30 PM A4 & S6 Horse Hitch – Draft Horse Ring 12:00 PM West Coast Amusements Midway Opens 4-H Cattle Show “Waterin’ Hole” Opens McCoy Carriages – wagon rides EnCana Parking Lot & Camping Area to Grounds Agriculture Kids Zone (4-H Bldg) 4-H Beef Show Draft Horse Halter Show & Log Skid 7:00 AM Gates Open (Admission Charge) Wrangler “Tough Enough to Wear Pink” 10:00 AM Parade (Downtown) 8:00 PM Schilds Kurjata Kids Calf Scramble – Grandstand
Accrington have sacked midfielder Paddy Lacey after he was given 14-month ban by the Football Association for taking cocaine.Lacey, 24, admitted breaching anti-doping rules after testing positive for Benzoylecgonine, a metabolite of cocaine, following Accrington’s game against Hartlepool on November 22.Accrington immediately suspended Lacey pending the outcome of disciplinary action and after the FA announced his suspension on Friday, the Sky Bet League Two club have terminated his contract.“The 24-year-old tested positive for a prohibited substance after the game at Hartlepool United in November 2016,” the club said in a statement.“He was immediately suspended by the club pending the outcome of the disciplinary action taken by the FA.“Upon the completion of those proceedings this week, the club took immediate action and terminated the contract of the player.“Accrington Stanley has strong values on anyone taking any prohibited substances and will always act in the strongest possible way to protect the integrity of the football club.“There will be no further comment.”Lacey joined Accrington on a free transfer from Barrow in July last year and made 17 appearances this season, but has not played since December 10.An FA statement read: “Patrick Lacey has been ordered to serve a 14-month suspension from all football and football activity after admitting a breach of The FA’s Anti-Doping Regulations.“The Accrington Stanley player provided an in-competition urine sample which contained the presence of Benzoylecgonine, a metabolite of cocaine.“The test was carried out after the Hartlepool United versus Accrington Stanley game on November 22, 2016.“The suspension, which followed an Independent Regulatory Commission Hearing, is effective from December 15, 2016, up to and including February 14, 2018.” 1 The 24-year-old tested positive for cocaine